PTGX - プロタゴニスト・セラピュ―ティクス (Protagonist Therapeutics Inc.)

PTGXのニュース

   Shorla Pharma Announces New Board Members, John Moloney and Tracy Woody  2020/11/10 08:00:00 Benzinga
DUBLIN and CLONMEL, Ireland , Nov. 10, 2020 /PRNewswire/ -- Shorla Pharma Limited ('Shorla'), an Irish specialty pharmaceutical company announces the appointment of two new non-executive board members, John Moloney , Chairman of DCC plc, and Tracy Woody , Executive Vice President, Corporate Strategy at Protagonist Therapeutics. "We are delighted to welcome two highly experienced executives to our Board." - Sharon Cunningham , CEO and Co-founder Shorla specializes in developing innovative oncology drugs, with a focus on rare, orphan and pediatric … Full story available on Benzinga.com
   Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update  2020/11/04 21:54:00 PR Newswire
NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate update. "The three clinical assets PTG-300, PN-943 and PTG-200, all discovered through…
   Protagonist Therapeutics Will earnings report, end it's winning streak? Stock market Insights & financial analysis  2020/11/04 17:51:00 Stock Market Daily
Protagonist Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen  2020/10/29 20:30:00 PR Newswire
NEWARK, Calif., Oct. 29, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that two additional oral peptide IL-23 receptor antagonist candidates from its collaboration agreement with Janssen Biotech, Inc., have been selected for advancement into clinical…
   Protagonist Therapeutics Inc (NASDAQ:PTGX) Given Consensus Rating of “Buy” by Analysts  2020/10/24 22:28:43 Daily Political
Shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) have earned an average recommendation of “Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have […]
   Shorla Pharma Announces New Board Members, John Moloney and Tracy Woody  2020/11/10 08:00:00 Benzinga
DUBLIN and CLONMEL, Ireland , Nov. 10, 2020 /PRNewswire/ -- Shorla Pharma Limited ('Shorla'), an Irish specialty pharmaceutical company announces the appointment of two new non-executive board members, John Moloney , Chairman of DCC plc, and Tracy Woody , Executive Vice President, Corporate Strategy at Protagonist Therapeutics. "We are delighted to welcome two highly experienced executives to our Board." - Sharon Cunningham , CEO and Co-founder Shorla specializes in developing innovative oncology drugs, with a focus on rare, orphan and pediatric … Full story available on Benzinga.com
   Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update  2020/11/04 21:54:00 PR Newswire
NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate update. "The three clinical assets PTG-300, PN-943 and PTG-200, all discovered through…
   Protagonist Therapeutics Will earnings report, end it's winning streak? Stock market Insights & financial analysis  2020/11/04 17:51:00 Stock Market Daily
Protagonist Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen  2020/10/29 20:30:00 PR Newswire
NEWARK, Calif., Oct. 29, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that two additional oral peptide IL-23 receptor antagonist candidates from its collaboration agreement with Janssen Biotech, Inc., have been selected for advancement into clinical…
   Protagonist Therapeutics Inc (NASDAQ:PTGX) Given Consensus Rating of “Buy” by Analysts  2020/10/24 22:28:43 Daily Political
Shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) have earned an average recommendation of “Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have […]
   The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review  2020/09/11 12:05:16 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 10) Agenus Inc (NASDAQ: AGEN ) Akouos Inc (NASDAQ: AKUS ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 10) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC )(reacted to results for the half-year) Burning Rock Biotech Ltd (NASDAQ: BNR ) Evofem Biosciences Inc (NASDAQ: EVFM ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Pandion Therapeutics Inc (NASDAQ: PAND ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) ( reacted to a negative late-stage clinical readout for investigational migraine drug) Stocks In Focus Roche Presents Positive Long-Term Data For Multiple Sclerosis Drug Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) announced …
   Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference  2020/09/10 20:30:00 Benzinga
NEWARK, Calif. , Sept. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference. … Full story available on Benzinga.com
   The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test  2020/08/27 12:02:06 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories (NYSE: ABT ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Fluidigm Corporation (NASDAQ: FLDM ) ( announced emergency use authorization for its saliva-based COVID-19 test) Generation Bio Co (NASDAQ: GBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PPD Inc (NASDAQ: PPD ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Silk Road Medical Inc (NASDAQ: SILK ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Polypid Ltd (NASDAQ: PYPD ) Stocks In Focus FDA Approves Companion Diagnostic Test For Clovis Oncology's Prostate Cancer Drug Clovis Oncology Inc (NASDAQ: CLVS ) said the FDA approved FoundationOne Liquid CDx, Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY )-owned Foundation Medicine's comprehensive liquid biopsy test for all solid tumors with multiple companion diagnostic indications, including for Rubraca tablets.
   The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout  2020/08/25 12:38:16 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDAQ: PRNB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Revance Therapeutics Inc (NASDAQ: RVNC ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) (FDA granted a third fast-track designation to its lead drug candidate, repotrectinib) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 24) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Kymera Therapeutics Inc (NASDAQ: KYMR ) (IPOed Friday) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Polypid Ltd (NASDAQ: PYPD ) Poseida Therapeutics, Inc. (NASDAQ: PSTX ) Recro Pharma Inc (NASDAQ: REPH ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Tricida Inc (NASDAQ: TCDA ) (FDA rejected its drug to treat metabolic acidosis and requested additional data) Unity Biotechnology Inc (NASDAQ: UBX ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Qiagen Launches Rapid …
   The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs  2020/06/19 11:41:54 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Alpine Immune Sciences Inc (NASDAQ: ALPN )( announced a licensing agreement with AbbVie Inc (NYSE: ABBV ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Castle Biosciences Inc (NASDAQ: CSTL ) Cytokinetics, Inc. (NASDAQ: CYTK ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Neubase Therapeutics Inc (NASDAQ: NBSE ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Ovid Therapeutics Inc (NASDAQ: OVID ) Passage Bio Inc (NASDAQ: PASG ) Pliant Therapeutics Inc (NASDAQ: PLRX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Royalty Pharma plc (NASDAQ: RPRX ) (IPOed Monday) Sarepta Therapeutics Inc (NASDAQ: SRPT )(announced a licensing agreement with Selecta Biosciences Inc (NASDAQ: SELB ) for licensing the latter's immune tolerance platform, ImmTOR for use in Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TELA Bio Inc (NASDAQ: TELA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Trevena Inc (NASDAQ: TRVN ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 18) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Stocks In Focus Mylan Wins Patent Lawsuit Against Biogen With Respect To Multiple Sclerosis Drug Mylan NV (NASDAQ: MYL ) said the U.S.

calendar